Howard C. Dittrich

NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA.

Alliance Pharmaceutical Corp. is a research & development company, which focused on transformed innovative scientific discovered into novel therapeutic and diagnostic agents. It currently focused on developed its lead product, Oxygent, an intravascular oxygen carrier designed to augment oxygen deliveryed in surgical patients. The company was founded by Duane J. Roth in 1983 and is headquartered in San Diego, CA.

Molecular Biosystems, Inc. develops, makes and sells ultrasound contrast imaging agents. The company was founded by Kenneth J. Widder, Richard H. Tullis, Drew E. Senyei and Lyle J. Arnold and is headquartered in San Diego, CA.

Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA.

Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH.

Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA.